Yahoo
As the U.S. market looks to rebound from a late-2024 slump, major indices like the S&P 500 and Nasdaq Composite have started 2025 with slight gains, hinting at potential recovery. Penny stocks, often representing smaller or newer companies, continue to offer intriguing opportunities despite being considered a throwback term. By focusing on those with strong financials and clear growth prospects, investors can uncover hidden value in these lesser-known stocks.
Yahoo
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that in light of the recent data monitoring committee (DMC) evaluation of the full dataset from the Reliance II Phase 3 study of the Company's REL-1017 program,
Yahoo
Relmada Therapeutics (RLMD) announced that the pre-planned interim analysis of Reliance II, conducted by the Independent Data Monitoring Committee, indicated that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance. Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder, to be used in combination with other approved anti-depressants. No new safety signals were reported. “We are
Yahoo
Health care stocks edged down late Wednesday afternoon with the NYSE Health Care Index and the Healt
Yahoo
Relmada Therapeutics (RLMD) said Wednesday that an Independent Data Monitoring Committee has determi
Yahoo
The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the cent
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CCRN | -52.45% | $584.87M | -16.30% | 0.00% |
CYCN | -52.04% | $7.89M | -19.17% | 0.00% |
PSTG | -25.13% | $21.34B | +68.05% | 0.00% |
MRVL | -22.23% | $101.74B | +72.38% | 0.20% |
CRM | -21.13% | $306.24B | +16.59% | 0.49% |
SN | -19.92% | $15.23B | +126.98% | 0.00% |
CMG | -19.78% | $79.52B | +25.62% | 0.00% |
TKO | -17.61% | $11.51B | +86.97% | 0.00% |
DAKT | -17.27% | $775.27M | +104.97% | 0.00% |
VRNT | -17.01% | $1.52B | -10.96% | 0.00% |
DPZ | -15.62% | $14.47B | -1.65% | 1.42% |
BRFS | -15.51% | $6.11B | +53.99% | 0.00% |
HUBS | -15.49% | $37.03B | +24.99% | 0.00% |
NOW | -15.45% | $217.77B | +41.72% | 0.00% |
DDOG | -15.29% | $46.47B | +7.78% | 0.00% |
PRO | -15.10% | $1.03B | -37.80% | 0.00% |
ALAB | -14.95% | $20.29B | +255.28% | 0.00% |
XPEL | -14.71% | $1.18B | -17.76% | 0.00% |
CHEF | -14.68% | $2.09B | +74.20% | 0.00% |
VSTA | -14.56% | $188.40M | -44.05% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EA | -<0.01% | $37.09B | +2.44% | 0.53% |
HWC | 0.01% | $5.03B | +30.58% | 2.54% |
CBRE | -0.01% | $41.24B | +59.81% | 0.00% |
APO | -0.01% | $93.88B | +71.80% | 1.09% |
LLYVK | -0.01% | $6.41B | +93.35% | 0.00% |
RMAX | -0.02% | $190.04M | 0.00% | 0.00% |
EXE | -0.02% | $24.91B | +41.38% | 2.12% |
CREG | -0.02% | $6.42M | -57.20% | 0.00% |
TAP | 0.03% | $11.33B | -12.49% | 3.19% |
RTO | 0.03% | $12.06B | -6.39% | 2.41% |
ASTS | -0.03% | $4.21B | +404.81% | 0.00% |
ZEUS | -0.03% | $374.83M | -47.68% | 1.77% |
HPE | 0.04% | $30.79B | +56.48% | 2.21% |
SYNA | 0.04% | $3.24B | -23.00% | 0.00% |
BKH | -0.04% | $4.23B | +17.33% | 4.40% |
EC | -0.04% | $17.74B | -26.37% | 18.23% |
ALTR | -0.04% | $9.42B | +29.31% | 0.00% |
CMCSA | 0.05% | $138.94B | -14.65% | 3.38% |
IONQ | -0.05% | $8.99B | +287.59% | 0.00% |
CM | -0.05% | $58.79B | +38.76% | 4.23% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GXO | 28.53% | $5.30B | -20.27% | 0.00% |
BASE | 27.17% | $856.41M | -30.85% | 0.00% |
SUNS | 26.90% | $94.25M | +20.44% | 4.61% |
PGEN | 25.38% | $325.08M | -8.26% | 0.00% |
ARWR | 22.34% | $2.37B | -42.64% | 0.00% |
ATXS | 21.65% | $437.37M | +9.00% | 0.00% |
ALEC | 21.45% | $164.53M | -70.88% | 0.00% |
MNST | 21.30% | $48.29B | -13.28% | 0.00% |
CPB | 21.29% | $11.70B | -10.18% | 3.81% |
ACET | 19.43% | $75.78M | -62.39% | 0.00% |
ALLO | 19.00% | $385.80M | -42.50% | 0.00% |
BMBL | 19.00% | $846.52M | -44.11% | 0.00% |
TOST | 18.83% | $20.95B | +112.26% | 0.00% |
BPT | 18.61% | $9.82M | -83.19% | 0.00% |
CDLX | 18.48% | $155.52M | -50.16% | 0.00% |
AMED | 18.40% | $3.01B | -3.13% | 0.00% |
XNCR | 18.29% | $1.40B | +1.83% | 0.00% |
TOL | 18.27% | $13.44B | +35.24% | 0.69% |
IRWD | 17.84% | $604.91M | -68.97% | 0.00% |
RYN | 17.78% | $3.90B | -16.26% | 4.37% |
Current Value
$0.401 Year Return
Current Value
$0.401 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KCCA | 15.39% | $105.80M | 0.87% |
ICLO | 14.27% | $287.53M | 0.2% |
ITB | 13.95% | $2.79B | 0.39% |
GNOM | 13.70% | $67.37M | 0.5% |
FMHI | 12.74% | $751.73M | 0.7% |
YOLO | 12.70% | $29.81M | 1.03% |
MUST | 12.18% | $419.74M | 0.23% |
ZIG | 12.18% | $47.45M | 0.84% |
MDIV | 11.90% | $442.66M | 0.68% |
XHB | 11.83% | $1.80B | 0.35% |
IBDQ | 11.49% | $3.18B | 0.1% |
PINK | 10.99% | $140.10M | 0.5% |
XBI | 10.71% | $5.97B | 0.35% |
TAN | 10.61% | $825.01M | 0.67% |
INFL | 10.59% | $1.08B | 0.85% |
HYSA | 10.57% | $30.05M | 0.55% |
ENZL | 10.52% | $76.10M | 0.5% |
SPRE | 10.44% | $149.46M | 0.5% |
LIT | 10.14% | $1.07B | 0.75% |
CNBS | 9.87% | $11.68M | 0.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
HEGD | <0.01% | $348.11M | 0.88% |
PBDC | -0.01% | $157.26M | 13.94% |
QUAL | 0.01% | $50.73B | 0.15% |
NACP | 0.02% | $57.53M | 0.49% |
PSFF | 0.02% | $437.54M | 0.88% |
RPAR | -0.02% | $531.90M | 0.5% |
QUS | -0.02% | $1.39B | 0.15% |
SCHQ | -0.03% | $692.86M | 0.03% |
SPYI | -0.05% | $2.75B | 0.68% |
CWI | -0.06% | $1.59B | 0.3% |
DVOL | -0.06% | $56.57M | 0.6% |
DCOR | 0.07% | $1.26B | 0.14% |
CEMB | 0.08% | $407.27M | 0.5% |
PFFR | -0.09% | $100.90M | 0.45% |
RING | 0.10% | $919.42M | 0.39% |
FDLO | -0.11% | $1.33B | 0.16% |
TLT | -0.12% | $51.71B | 0.15% |
GLOV | 0.12% | $1.07B | 0.25% |
EPOL | 0.12% | $196.40M | 0.59% |
SMH | 0.13% | $23.67B | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IGV | -14.32% | $9.64B | 0.41% |
HYZD | -13.35% | $170.56M | 0.43% |
SKYY | -10.22% | $3.57B | 0.6% |
SEIX | -9.81% | $308.05M | 0.62% |
UNG | -9.61% | $852.04M | 1.06% |
FDN | -8.87% | $6.58B | 0.51% |
BCD | -8.65% | $242.75M | 0.3% |
EQLS | -8.60% | $9.15M | 1% |
CLOU | -8.40% | $351.81M | 0.68% |
DBB | -8.37% | $109.38M | 0.77% |
QGRO | -7.95% | $1.15B | 0.29% |
WCLD | -7.76% | $459.62M | 0.45% |
XSW | -7.74% | $492.83M | 0.35% |
DAPP | -7.57% | $208.09M | 0.51% |
BUG | -7.53% | $798.07M | 0.5% |
PHDG | -7.28% | $114.75M | 0.39% |
BOXX | -7.28% | $4.76B | 0.1949% |
EWG | -7.28% | $870.67M | 0.5% |
BCI | -7.21% | $1.37B | 0.26% |
CMDY | -7.19% | $292.03M | 0.28% |